All India Institute of Medical Sciences, Bhopal, India.
Royal Marsden Hospital, London, United Kingdom.
Urology. 2023 Dec;182:5-13. doi: 10.1016/j.urology.2023.09.014. Epub 2023 Sep 27.
To determine the impact of radical local treatment (RLT) on overall survival (OS) and other survival outcomes in patients with OligoMetastatic Prostate Cancer (OMPC).
We performed a meta-analysis of randomized controlled trials (RCTs) published in the MEDLINE and CENTRAL databases until May 2023. We included RCTs that randomized patients to RLT (either radical prostatectomy [RP] or external beam radiotherapy [EBRT]) and standard of care and reported on OMPC. Our primary objective was to analyze OS with a minimum median follow-up of 4years (PROSPERO-CRD42023422736).
We analyzed 3 RCTs, presenting data across 5 papers. OS was significantly higher in the RLT group (HR - 0.643, 95%CI 0.514-0.8, P-value <.001). The data on EBRT was drawn from 520 patients and that of RP was from 85. The post-hoc power analysis showed 81% power to detect a difference of 10% with an alpha error of 0.01. Pooled prevalence of grade 3-4 bowel and bladder toxicity was 4.5%. Health-Related Quality of Life was similar in both groups (mean difference - 1.54, 95%CI -0.625 -3.705, P-value .163). The risk of bias as per the RoB2 tool was low for all domains and overall bias. As per GRADE criteria, the certainty of evidence was high.
Our meta-analysis underscores the evidence-based significance of RLT, particularly emphasizing the benefits of EBRT in patients with OMPC. However, the findings should be interpreted with caution due to the limited number of studies and the relatively small sample sizes, especially in the RP subgroup. Future investigations in OMPC should consider incorporating EBRT in their standard treatment approach.
确定根治性局部治疗(RLT)对寡转移前列腺癌(OMPC)患者总生存(OS)和其他生存结局的影响。
我们对截至 2023 年 5 月在 MEDLINE 和 CENTRAL 数据库中发表的随机对照试验(RCT)进行了荟萃分析。我们纳入了将患者随机分配至 RLT(根治性前列腺切除术[RP]或外照射放疗[EBRT])和标准治疗,并报告了 OMPC 结果的 RCT。我们的主要目的是分析 OS,最小随访时间为 4 年(PROSPERO-CRD42023422736)。
我们分析了 3 项 RCT,共涉及 5 篇论文的数据。RLT 组的 OS 显著更高(HR - 0.643,95%CI 0.514-0.8,P 值 <.001)。EBRT 的数据来自 520 例患者,RP 的数据来自 85 例患者。事后功效分析显示,检测 10%差异的功效为 81%,α错误为 0.01。3-4 级肠和膀胱毒性的汇总发生率为 4.5%。两组的健康相关生活质量相似(平均差值 - 1.54,95%CI -0.625-3.705,P 值.163)。根据 RoB2 工具,所有领域和整体偏倚的风险都较低。根据 GRADE 标准,证据的确定性为高。
我们的荟萃分析强调了 RLT 的循证意义,特别是强调了 EBRT 对 OMPC 患者的益处。然而,由于研究数量有限,特别是在 RP 亚组中样本量相对较小,因此应谨慎解释这些发现。未来对 OMPC 的研究应考虑将 EBRT 纳入其标准治疗方法。